<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article33</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/ARISTOTLE" style="display:block; margin-bottom:10px;">ARISTOTLE Original</a></li>
<h2><strong>ARISTOTLE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Apixaban versus Warfarin in Patients with Atrial Fibrillation".The New England Journal of Medicine. 2011. 365:981-992.PubMed•Full text•PDFContents<br/>
<br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcome<br/>
8.2Secondary Outcomes<br/>
9Funding<br/>
10Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with atrial fibrillation and at least one additional risk factor for stroke, is apixaban superior to warfarin in preventing stroke or systemic embolism?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with atrial fibrillation, apixaban is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Warfarin, effective in stroke prevention for patients with atrial fibrillation, is limited by its narrow therapeutic range, interactions, and bleeding risk. Apixaban, a factor Xa inhibitor, demonstrates superiority over warfarin in stroke prevention, fewer bleeding events, and reduced mortality.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines have not been explicitly adjusted to reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial<br/>
<br/>
N=18,201 patients with atrial fibrillation<br/>
Apixaban 5 mg PO BID (n=9120)<br/>
Warfarin to INR 2.0-3.0 (n=9081)<br/>
Setting: 1034 sites in 39 countries<br/>
Enrollment: 2006-2010<br/>
Median follow-up: 1.8 years<br/>
Analysis: Intention-to-treat<br/>
Primary Efficacy Outcome: Stroke or systemic embolism<br/>
Primary Safety Outcome: Major bleeding<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
Atrial fibrillation/flutter, at least one risk factor for stroke<br/>
<br/>
Exclusion Criteria<br/>
Reversible atrial fibrillation, moderate/severe mitral stenosis, conditions necessitating anticoagulation, recent stroke, aspirin &gt;165 mg/day, severe renal impairment<br/>
<br/>
Baseline Characteristics<br/>
Median age: 70 years; 35.3% female; mean CHADS2 score: 2.1<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Apixaban at a dose of 5 mg BID (2.5 mg BID in a subset)<br/>
Warfarin with INR target of 2.0-3.0<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
Stroke or systemic embolism<br/>
Apixaban: 1.27% per year<br/>
Warfarin: 1.60% per year (HR 0.79; 95% CI, 0.66-0.95; P&lt;0.001 for noninferiority; P=0.01 for superiority)<br/>
<br/>
Secondary Outcomes<br/>
Major bleeding<br/>
Apixaban: 2.13% per year<br/>
Warfarin: 3.09% per year (HR 0.69; 95% CI, 0.60-0.80; P&lt;0.001)<br/>
Death from any cause<br/>
Apixaban: 3.52% per year<br/>
Warfarin: 3.94% per year (HR 0.89; 95% CI, 0.80-0.99; P=0.047)<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Bristol-Myers Squibb and Pfizer<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
For more information, this study is registered on ClinicalTrials.gov, number NCT00412984.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
